国药现代(600420.SH)：全资子公司获得药品注册证书

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), has received approval from the National Medical Products Administration for its Hydromorphone Hydrochloride Injection, marking a significant step in expanding its product line in the anesthetic and analgesic sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has been granted a drug registration certificate for Hydromorphone Hydrochloride Injection, with the certificate number 2025S03532 [1] - Hydromorphone, a semi-synthetic opioid, has been in clinical use since 1926 and is indicated for patients requiring opioid analgesia [1] Group 2: Market Impact - The approval signifies that the company is now qualified to produce and sell this product in the domestic market, enhancing its competitive edge [1] - The addition of Hydromorphone Hydrochloride Injection to the company's anesthetic and analgesic product line is expected to positively influence its future development [1]